Jefferies Group’s Pacific Biosciences PACB Stock Holding History

Jefferies Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$174K	Sell	30,000 -20,000	-40%	-$115K	﹤0.01%	1385
2022 Q2	$221K	Buy	+50,000	New	+$304K	﹤0.01%	1254
2019 Q4	–	Sell	-52,948	Closed	-$273K	–	2874
2019 Q3	$273K	Sell	52,948 -23,114	-30%	-$129K	﹤0.01%	2224
2019 Q2	$460K	Sell	76,062 -72,299	-49%	-$507K	﹤0.01%	1711
2019 Q1	$1.07M	Buy	148,361 +72,813	+96%	+$527K	0.01%	1236
2018 Q4	$559K	Buy	+75,548	New	+$479K	﹤0.01%	1420
2014 Q4	–	Sell	-13,288	Closed	-$65K	–	2254
2014 Q3	$65K	Buy	+13,288	New	+$69.5K	﹤0.01%	1962
2014 Q2	–	Sell	-10,753	Closed	-$58K	–	2303
2014 Q1	$58K	Buy	+10,753	New	+$68K	﹤0.01%	1888

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group's PACB Position: Q3 2022 in Review

Jefferies Group reduced its Pacific Biosciences (PACB) stake by 40% in Q3 2022, selling an estimated $115K and leaving 30,000 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Jefferies Group first reported a position in PACB in Q1 2014 and has held it in 8 quarters since. The position peaked at $1.07M in Q1 2019. 227 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

Jefferies Group held 30,000 shares of Pacific Biosciences worth $174K as of Q3 2022.
Jefferies Group sold 20,000 Pacific Biosciences shares in Q3 2022, an estimated $115K.
Pacific Biosciences made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1385 holding.
Jefferies Group first reported a position in Pacific Biosciences in Q1 2014 and has held it in 8 quarters since.
Jefferies Group's Pacific Biosciences position peaked at $1.07M in Q1 2019.
227 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.